CRDL vs. OTLK, VIGL, LIFE, BLUE, BCAB, ZURA, AGEN, OMGA, DBVT, and SGMO
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Outlook Therapeutics (OTLK), Vigil Neuroscience (VIGL), aTyr Pharma (LIFE), bluebird bio (BLUE), BioAtla (BCAB), Zura Bio (ZURA), Agenus (AGEN), Omega Therapeutics (OMGA), DBV Technologies (DBVT), and Sangamo Therapeutics (SGMO). These companies are all part of the "biological products, except diagnostic" industry.
Cardiol Therapeutics (NASDAQ:CRDL) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking.
12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Outlook Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Outlook Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Outlook Therapeutics received 141 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. Likewise, 70.32% of users gave Outlook Therapeutics an outperform vote while only 48.15% of users gave Cardiol Therapeutics an outperform vote.
In the previous week, Outlook Therapeutics had 8 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 8 mentions for Outlook Therapeutics and 0 mentions for Cardiol Therapeutics. Outlook Therapeutics' average media sentiment score of 0.41 beat Cardiol Therapeutics' score of 0.00 indicating that Outlook Therapeutics is being referred to more favorably in the news media.
Cardiol Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 79.64%. Outlook Therapeutics has a consensus target price of $46.43, suggesting a potential upside of 460.01%. Given Outlook Therapeutics' higher possible upside, analysts clearly believe Outlook Therapeutics is more favorable than Cardiol Therapeutics.
Cardiol Therapeutics has higher revenue and earnings than Outlook Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cardiol Therapeutics' return on equity of -76.18% beat Outlook Therapeutics' return on equity.
Cardiol Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500.
Summary
Cardiol Therapeutics and Outlook Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
